Rafferty Asset Management
NBIX icon

Rafferty Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Rafferty Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.77M Sell
36,232
-2,823
-7% -$375K 0.02% 383
2025
Q4 		$5.54M Sell
39,055
-19,646
-33% -$2.85M 0.02% 407
2025
Q3 		$8.24M Sell
58,701
-20,445
-26% -$2.77M 0.03% 318
2025
Q2 		$9.95M Sell
79,146
-21,661
-21% -$2.48M 0.03% 270
2025
Q1 		$11.1M Sell
100,807
-6,204
-6% -$786K 0.05% 243
2024
Q4 		$14.6M Sell
107,011
-33,824
-24% -$4.18M 0.05% 216
2024
Q3 		$16.2M Buy
140,835
+17,837
+15% +$2.45M 0.06% 182
2024
Q2 		$16.9M Buy
122,998
+57,128
+87% +$7.83M 0.06% 173
2024
Q1 		$9.08M Sell
65,870
-10,679
-14% -$1.46M 0.03% 296
2023
Q4 		$10.1M Sell
76,549
-4,941
-6% -$569K 0.04% 277
2023
Q3 		$9.17M Sell
81,490
-7,541
-8% -$794K 0.05% 246
2023
Q2 		$8.4M Buy
89,031
+18,043
+25% +$1.76M 0.05% 251
2023
Q1 		$7.19M Buy
70,988
+2,334
+3% +$243K 0.05% 287
2022
Q4 		$8.2M Buy
68,654
+3,525
+5% +$413K 0.07% 252
2022
Q3 		$6.92M Buy
65,129
+24,727
+61% +$2.51M 0.07% 228
2022
Q2 		$3.94M Sell
40,402
-19,494
-33% -$1.8M 0.04% 334
2022
Q1 		$5.62M Sell
59,896
-6,304
-10% -$534K 0.03% 358
2021
Q4 		$5.64M Buy
66,200
+33,986
+106% +$3.13M 0.03% 341
2021
Q3 		$3.09M Buy
32,214
+5,764
+22% +$544K 0.02% 460
2021
Q2 		$2.57M Sell
26,450
-7,886
-23% -$756K 0.02% 585
2021
Q1 		$3.34M Buy
34,336
+24,002
+232% +$2.52M 0.02% 420
2020
Q4 		$991K Sell
10,334
-9,432
-48% -$911K 0.01% 497
2020
Q3 		$1.9M Buy
19,766
+8,621
+77% +$997K 0.02% 431
2020
Q2 		$1.36M Buy
11,145
+6,864
+160% +$759K 0.02% 460
2020
Q1 		$371K Sell
4,281
-31,334
-88% -$3.07M 0.02% 384
2019
Q4 		$3.83M Sell
35,615
-31,629
-47% -$3.31M 0.06% 176
2019
Q3 		$6.06M Buy
67,244
+8,325
+14% +$778K 0.09% 125
2019
Q2 		$4.97M Sell
58,919
-5,611
-9% -$461K 0.09% 165
2019
Q1 		$5.68M Buy
+64,530
New +$5.39M 0.09% 117

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management's NBIX Position: Q1 2026 in Review

Rafferty Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 7.2% in Q1 2026, selling an estimated $375K and leaving 36,232 shares worth $4.77M. The position accounts for 0.02% of the portfolio, ranked #383.

Rafferty Asset Management first reported a position in NBIX in Q1 2019 and has held it in 29 quarters since. The position peaked at $16.9M in Q2 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Rafferty Asset Management held 36,232 shares of Neurocrine Biosciences worth $4.77M as of Q1 2026.
  • Rafferty Asset Management sold 2,823 Neurocrine Biosciences shares in Q1 2026, an estimated $375K.
  • Neurocrine Biosciences made up 0.02% of Rafferty Asset Management's portfolio in Q1 2026, its #383 holding.
  • Rafferty Asset Management first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 29 quarters since.
  • Rafferty Asset Management's Neurocrine Biosciences position peaked at $16.9M in Q2 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.